Tumor Markers Yesterday, Today & Tomorrow. Steven E. Zimmerman M.D. Vice President & Chief Medical Director
|
|
- Erik Singleton
- 6 years ago
- Views:
Transcription
1 Tumor Markers Yesterday, Today & Tomorrow Steven E. Zimmerman M.D. Vice President & Chief Medical Director
2 Tumor Marker - Definition Substances produced by cancer cells or other cells in response to cancer or certain benign conditions Most are made by normal cells as well as cancer cells Can be found in blood, urine, stool, tumor tissue, or other tissues or bodily fluids Most are proteins, but more recently patterns of gene expression and changes to DNA have been used 2
3 How are tumor markers used? Screening and early detection of cancer Diagnosing cancer Determining prognosis for certain cancers Determining if certain treatments are likely to work Determining how well treatment is working Looking for recurrent cancer 3
4 SCREENING 4
5 Principles of Cancer Screening Likelihood of test correctly identifying cancer: Sensitivity number of cancers missed Specificity number of cancers inappropriately diagnosed Likelihood of cancer being present Harm from follow-up procedures Suitable treatment available & appropriate Does early detection improve outcomes Lead-time bias Will cancer ever need treatment The extent to which the cancer is treatable 5
6 Cancers Where Screening May Useful Breast Cancer Cervical Cancer Lower GI Cancer Prostate Cancer Lung Cancer Oral Cancer Skin Cancer 6
7 Cancers Where Screening May Useful Breast Cancer Cervical Cancer Lower GI Cancer Prostate Cancer Lung Cancer Oral Cancer Skin Cancer Of all these cancers, only prostate cancer has a tumor marker that has efficacy as a screening test 7
8 Relationship of Incidence of Prostate Cancer to PSA Testing PSA testing rates increased from 1.2% in 1988 to 40% in 1994 Percent of Caucasian males with 1 st PSA peaked at 19% in 1992, and subsequently declined
9 Estimated Probability of Prostate Cancer with Normal DRE Barry M. N Engl J Med 2001;344:
10 PSA Possible Improvements Age-specific Reference Ranges (lower cut-off values) Age ng/ml Age ng/ml Age ng/ml Age ng/ml PSA velocity > 0.75 ng/ml/yr Free-PSA ratio (free PSA/total PSA) in percentage PSA between 4.0 ng/ml and 10.0 mg/ml & normal DRE Free-PSA% < 10% up to 56% with cancer Free PSA% > 25% 8% with cancer
11 Prostate Cancer Antigen 3 (PCA3) Gene only expressed in human prostate tissue, and highly overexpressed in prostate cancer Compared with PSA: Lower sensitivity, higher specificity Better positive and negative predictive value Useful in predicting presence of prostate cancer in men undergoing repeat prostate biopsy Assay is ratio of PCA3 RNA to PSA RNA in post-digital rectal exam first voided urine PCA3 score <25 associated with decrease likelihood of positive biopsy 11
12 Incidence of and Mortality from Prostate Cancer in the United States, 1987 through 1997 Barry M. N Engl J Med 2001;344:
13 Question: For asymptomatic men in the general population, do the benefits of PSA testing for prostate cancer screening outweigh the potential harms? 13
14 Benefits of PSA Screening Although screening leads to more prostate cancer diagnosis, no statistically significant differences in overall or prostate cancer-specific mortality has been demonstrated European Randomised Study of Screening for Prostate Cancer (ERSPC) 11 year follow-up 162,388 men between 55 and 69 years of age 20% reduction in prostate cancer-specific mortality for men in the screening arm 14
15 Harms with PSA Screening Harms associated with diagnostic evaluation included infection, bleeding and urinary difficulties Two population-based studies reported an increase over time in the 30 day hospitalization rate for infection-related causes False positive rate was % 15
16 Conclusions It is uncertain whether the benefits associated with PSA screening are worth the harms associated with screening and subsequent unnecessary treatment Because the evidence does not clearly inform the issue around PSA testing and its downstream effects, the importance of informed and shared decision-making becomes paramount 16
17 Prostate Cancer Screening in Average and High Risk Men: ACS (2010); USPSTF (2012) Recommendation ACS USPSTF PSA Testing The ACS recommends that asymptomatic men who have at least a 10-year life expectancy should have an opportunity to make an informed decision with their health care provider about whether to be screened for prostate cancer, after receiving information about the uncertainties, risks, and potential benefits associated with prostate cancer screening. The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)-based screening for prostate cancer. This is a grade D recommendation.
18 CEA as a Screening Test CEA described in 1965, present in both fetal colon and colon adenocarcinoma Normal limits: 2.5 ng/ml nonsmokers 5.0 ng/ml smokers Elevated CEA for nonmalignant disorders peptic ulcer, pancreatitis, diverticulitis, inflammatory bowel disease
19 CEA as a Screening Test cont. Most elevations are in the 2.5 ng/ml to 10.0 ng/ml range majority no cause found Few will have undetected malignancy majority of these will be colorectal cancers < 25% with tumors confined to colon will have elevations Sensitivity increases with advancing tumor stage 50% with tumor extension to lymph nodes 75% with distant metastasis Specificity and positive predictive value increases with higher cutoff levels
20 CEA as a Screening Test - Conclusion Clinically, CEA has no role as a screening test for any malignancy While it has been demonstrated that CEA elevations are associated with increased allcause mortality, it s use as a test for risk selection remains highly controversial
21 ASSIST WITH DIAGNOSIS
22 Tumor Markers That Assist with Diagnosis Tumor Marker Cancer Type Tissue Analyzed Alpha-fetoprotein (AFP) Liver cancer Blood BCR-ABL fusion gene CML Blood &/or bone marrow CA-125 Ovarian Blood Calcitonin Medullary thyroid cancer Blood Chromogranin A (CgA) Neuroendocrine tumors Immunoglobulins Multiple myeloma & Waldenström macroglobulinemia Blood Blood or urine
23 Tumor Markers That Assist with Diagnosis Tumor Marker Cancer Type Tissue Analyzed KIT Prostate-specific antigen (PSA) GI stromal tumor & mucosal melanoma Prostate cancer Tumor Blood
24 Case Study Assisting with Diagnosis 63 y.o. male applying for $750, year Term Paramedical exam is unremarkable Labs reveal calcium level at upper limits of normal, serum globulin level slightly greater than serum albumin level, and small amount of protein in the urine APS reveals recent physical with mild anemia Referred back to his AP for further evaluation Follow-up labs revealed a monoclonal IgG kappa spike, with Bence-Jones protein in the urine Bone marrow aspirate and biopsy showed increased number of plasma cells
25 DETERMINE PROGNOSIS
26 Tumor Markers That Help Assess Prognosis Tumor Marker Cancer Type Tissue Analyzed ALK gene rearrangements Non-small cell lung cancer & anaplastic large cell lymphoma Alpha-fetoprotein (AFP) Germ cell tumors Beta-2-microglobulin (B2M) Beta-human chorionic gonadotropin (ß-hCG) EGFR mutation analysis Lactate dehydrogenase (LDH) Multiple myeloma, CLL, & some lymphomas Choriocarcinoma & testicular cancer Non-small cell lung cancer Germ cell tumors Tumor Blood Blood, urine or CSF Blood or urine Tumor Blood
27 Tumor Markers That Help Assess Prognosis Tumor Marker Cancer Type Tissue Analyzed Urokinase plasminogen activator (upa) & plasminogen activator (PAI-1) 5-Protein signature (Ova1) 21-Gene signature (Oncotype DX) 70-Gene signature (Mammaprint) Breast cancer Ovarian cancer Breast cancer Breast cancer Tumor Blood Tumor Tumor
28 GUIDE THERAPY
29 Tumor Markers That Help Guide Therapy Tumor Marker Cancer Type Tissue Analyzed ALK gene rearrangements BRAF mutation V600E Non-small cell lung cancer & anaplastic large cell lymphoma Cutaneous melanoma & colorectal cancer Tumor Tumor CD20 Non-Hodgkin s lymphoma Blood EGFR mutation analysis Estrogen receptor (ER)/ Progesterone receptor (PR) Non-small cell lung cancer Breast cancer Tumor Tumor
30 Tumor Markers That Help Guide Therapy Tumor Marker Cancer Type Tissue Analyzed HER2/neu KIT KRAS mutation analysis Breast cancer, gastric cancer & esophageal cancer Gastrointestinal stromal tumor & mucosal melanoma Colorectal cancer & non-small cell lung cancer Tumor Tumor Tumor
31 Case Study Guide to Therapy 42 y.o. female applying for $1,000,000 UL In March, 2010, she was found to have a 1.5 cm left breast mass Needle biopsy revealed poorly differentiated infiltrating ductal adenocarcinoma She underwent lumpectomy followed by radiation therapy Pathology on the lumpectomy specimen revealed a 1.5 cm poorly differentiated adenocarcinoma with clear margins; sentinel lymph node biopsy was negative ER/PR receptors were negative; HER2/neu was positive
32 EVALUATE RESPONSE TO TREATMENT
33 Tumor Markers That Determine Response to Therapy Tumor Marker Cancer Type Tissue Analyzed Alpha-fetoprotein (AFP) Liver cancer & germ cell tumors Beta-2-microglobulin (B2M) Beta-human chorionic gonadotropin (ß-hCG) Multiple myeloma, CLL, & some lymphomas Choriocarcinoma & testicular cancer Blood CA15-3/CA27.29 Breast cancer Blood CA19-9 Pancreatic cancer, gallbladder cancer, bile duct cancer, & gastric cancer Blood, urine or CSF Urine or blood Blood
34 Tumor Markers That Determine Response to Therapy Tumor Marker Cancer Type Tissue Analyzed CA-125 Ovarian cancer Blood Calcitonin Medullary thyroid cancer Blood Chromogranin A (CgA) Neuroendocrine tumors Blood Fibrin/fibrinogen Bladder cancer Urine HE4 Ovarian cancer Blood Nuclear matrix protein 22 Prostate-specific antigen (PSA) Bladder cancer Prostate cancer Urine Blood Thyroglobulin Thyroid cancer Blood
35 Case Study Response to Therapy 28 y.o. male applying for $500, year Term In 2009, found to have a testicular mass Orchiectomy was performed, with pathology revealing mixed embryonal cell and teratocarcinoma Metastatic evaluation showed retroperitoneal lymph node enlargement, and a 4 cm hilar mass ß-hCG was elevated at 75 miu/ml (0-5 miu/ml) and AFP was elevated at 27 µg/l (<10 µg/l) He received 4 cycles of chemotherapy, with return of tumor markers to normal, and resolution of the retroperitoneal adenopathy A 2 cm residual hilar mass remains, and is stable
36 DETECTION OF RECURRENCE
37 Tumor Markers Used to Detect Recurrence Tumor Marker Cancer Type Tissue Analyzed Alpha-fetoprotein (AFP) Beta-human chorionic gonadotropin (ß-hCG) Liver cancer & germ cell tumors Choriocarcinoma & testicular cancer Blood CA15-3/CA27.29 Breast cancer Blood CA-125 Ovarian cancer Blood Calcitonin Medullary thyroid cancer Blood Carcinoembryonic antigen (CEA) Colorectal cancer & breast cancer Blood or urine Blood
38 Tumor Markers Used to Detect Recurrence Tumor Marker Cancer Type Tissue Analyzed Chromogranin A (CgA) Chromosomes 3, 7, 17 & 9p21 Cytokeratin fragments 21-1 Neuroendocrine tumors Bladder cancer Lung cancer Blood Urine Blood HE4 Ovarian cancer Blood Immunoglobulins Prostate-specific antigen (PSA) Multiple myeloma & Waldenström macroglobulinemia Prostate cancer Blood or urine Blood Thyroglobulin Thyroid cancer Blood
39 Case Study Tumor Recurrence Monitoring 67 y.o. male applying for $10,000,000 UL In 05/2004, presented with PSA = 5.7 ng/ml DRE was negative, TRUS showed no masses, TRUSguided biopsies revealed Gleason s 6 prostate cancer in 5/12 cores Treated with radical prostatectomy Path showed Gleason 7 prostate cancer in both lobes, margins and seminal vesicles clear Post-op PSA <0.04 ng/ml PSA in 4/13 was 0.1 ng/ml Current PSA is 1.2 ng/ml
Tumor Markers & Cytopathology
Tumor Markers & Cytopathology Objectives: After learning, student should be able to 1. Describe the basic concepts of tumor markers and Asst. Prof. Prasit Suwannalert, Ph.D. (Email: prasit.suw@mahidol.ac.th)
More informationTumour Markers. For these reasons, only a handful of tumour markers are commonly used by most doctors.
Tumour Markers What are Tumour Markers? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer
More informationTUMOR M ARKERS MARKERS
TUMOR MARKERS M.Shekarabi IUMS Definition Many cancers are associated with the abnormal production of some molecules l which h can be measured in plasma. These molecules are known as tumor markers. A good
More informationCase #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ).
SOLID TUMORS WORKSHOP Cases for review Prostate Cancer Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ). January 2009 PSA 4.4, 20% free; August 2009 PSA 5.2; Sept 2009
More informationKimberly Rohan ANP-BC, AOCN Nurse Practitioner Edward Cancer Center
Kimberly Rohan ANP-BC, AOCN Nurse Practitioner Edward Cancer Center Objective The nurse will be able to explain biomarkers and their implications to patient s prescribed treatment plan Biomarkers Use in
More informationClinical Biochemistry Department City Hospital
Cancer Biochemistry and Tumour Markers Clinical Biochemistry Department City Hospital In this lecture Cancer basics Definition of Tumour Marker (TM) What is the perfect TM? History of TMs Examples of TMs
More informationCancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC
Cancers of unknown primary : Knowing the unknown Prof. Ahmed Hossain Professor of Medicine SSMC Definition Cancers of unknown primary site (CUPs) Represent a heterogeneous group of metastatic tumours,
More informationTake Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules
Take Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules Case 1 72 year old white female presents with a nodular thyroid. This was biopsied in
More informationProstate Case Scenario 1
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
More informationperformed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.
Hello, I am Maura Polansky at the University of Texas MD Anderson Cancer Center. I am a Physician Assistant in the Department of Gastrointestinal Medical Oncology and the Program Director for Physician
More informationOncology General Principles L A U R I E S I M A R D B R E A S T S U R G I C A L O N C O L O G Y F E L L O W D E C E M B E R
Oncology General Principles L A U R I E S I M A R D B R E A S T S U R G I C A L O N C O L O G Y F E L L O W D E C E M B E R 2 0 1 2 Objectives Discuss Diagnostic and staging strategies in oncology Know
More informationA Practicum Approach to CS: GU Prostate, Testis, Bladder, Kidney, Renal Pelvis. Jennifer Ruhl, RHIT, CCS, CTR Janet Stengel, RHIA, CTR
A Practicum Approach to CS: GU Prostate, Testis, Bladder, Kidney, Renal Pelvis Jennifer Ruhl, RHIT, CCS, CTR Janet Stengel, RHIA, CTR Survey Questions and Answers 250 Responses 2 Question #1 A gentleman
More informationList of Available TMAs in the PRN
TMA RPCI_BrainCa01 RPCI_BrCa03 RPCI_BrCa04 RPCI_BrCa05 RPCI_BrCa0 RPCI_BrCa07 RPCI_BrCa08 RPCI_BrCa15 RPCI_BrCa1 RPCI_BrCa17 RPCI_BrCa18 RPCI_BrCa19 RPCI_BrCa20 RPCI_BrCa21 RPCI_BrCa24 RPCI_BrCa25 RPCI_BrCa2
More informationTumour Markers as screening tests for cancer: is it practical?
Tumour Markers as screening tests for cancer: is it practical? Dr Tong SF MBBS (UM) MMed (Fam Med) (UKM) PhD (Sydney) Department of Family Medicine Faculty of Medicine UKM Is it practical for? Detecting
More informationCancer and Homeopathy
Cancer and Homeopathy Dr.Deepak Dass, BHMS (CU) dr.deepaklive@gmail.com Cancer or malignant tumour is a group of disease involving abnormal cell growth with potential to invade or spread to other parts
More informationProstate Overview Quiz
Prostate Overview Quiz 1. The path report reads: Gleason 3 + 4 = 7. The Gleason s score is a. 3 b. 4 c. 7 d. None of the above 2. The path report reads: Moderately differentiated adenocarcinoma of the
More information2018 New Required Data Items for Hospitals
2018 New Required Data Items for Hospitals The NJSCR is a population-based registry, mandated by state law, that collects data on all cancer cases diagnosed and/or treated in New Jersey since October 1,
More informationLectures in Holistic Medicine
Lectures in Holistic Medicine 10th in a series of 10 : Cancer part 2 Jakob Jaggy hmd www.foothillholistic.com Organizations I support AHMA www.holisticmedicine.org FoCuS www.foothillsustainability.org
More information-The cause of testicular neoplasms remains unknown
- In the 15- to 34-year-old age group, they are the most common tumors of men. - include: I. Germ cell tumors : (95%); all are malignant. II. Sex cord-stromal tumors: from Sertoli or Leydig cells; usually
More informationAppendix H 2018 FCDS Required Site Specific Data Items (SSDIs)
Below is the short list of Site Specific Data Items (SSDI) Required by FCDS for 2018. The list may be subject to changes. FCDS requires only a subset of the 136 total SSDIs available to be reported as
More informationBIOLOGY OF CANCER. Definition: Cancer. Why is it Important to Understand the Biology of Cancer? Regulation of the Cell Cycle 2/13/2015
BIOLOGY OF CANCER Why is it Important to Understand the Biology of Cancer? Cynthia Smith, RN, BA, MSN, AOCN Oncology Clinical Nurse Specialist Harrison Medical Center Definition: Cancer Regulation of the
More informationProstate Cancer. Biomedical Engineering for Global Health. Lecture Fourteen. Early Detection. Prostate Cancer: Statistics
Biomedical Engineering for Global Health Lecture Fourteen Prostate Cancer Early Detection Prostate Cancer: Statistics Prostate gland contributes enzymes, nutrients and other secretions to semen. United
More informationOncology Clinical Program Update. William Sause Medical Director Oncology Clinical Program
Oncology Clinical Program Update William Sause Medical Director Oncology Clinical Program Outline Cancer Program Background Screening Quality Care New Technology Contact Information Cancer Cases Utah 2011
More informationOBESITY AND CANCER NEW FINDINGS
LECTURE #5 1 2 3 OBESITY AND CANCER NEW FINDINGS ~30% of adults are obese (BMI > 30) ~35% of adults are overweight (BMI 25-30) Women: Uterine cancer 6-fold Men: Kidney cancer 5-fod Liver cancer 6-fold
More informationSEER Summary Stage Still Here!
SEER Summary Stage Still Here! CCRA NORTHERN REGION STAGING SYMPOSIUM SEPTEMBER 20, 2017 SEER Summary Stage Timeframe: includes all information available through completion of surgery(ies) in the first
More informationCase Scenario 1. 4/19/13 Bone Scan: No scintigraphic findings to suggest skeletal metastases.
Case Scenario 1 3/8/13 H&P 68 YR W/M presents w/elevated PSA. Patient is a non-smoker, current alcohol use. Physical Exam: On digital rectal exam the sphincter tone is normal and there is a 1 cm nodule
More informationNeoplasia 2018 lecture 11. Dr H Awad FRCPath
Neoplasia 2018 lecture 11 Dr H Awad FRCPath Clinical aspects of neoplasia Tumors affect patients by: 1. their location 2. hormonal secretions 3. paraneoplastic syndromes 4. cachexia Tumor location Even
More informationBarriers to Understanding
Behind the Scenes: The Critical Importance of Cancer Cell Pathology and the Pathologist Sherry T. Emery, M.D., Chief of Pathology Northeast Health System Barriers to Understanding Questions for 2010 What
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationMCR: MANAGEMENT OF 2018 CHANGES. By: Maricarmen Traverso-Ortiz MPH, CGG, CTR
MCR: MANAGEMENT OF 2018 CHANGES By: Maricarmen Traverso-Ortiz MPH, CGG, CTR LEARNING OBJECTIVES Discuss a summary of the new changes for 2018 Overview of how the Maryland Cancer Registry is managing and
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationMonitoring Patients Undergoing Cancer Therapy. By Timothy K. Egan
F E A T U R E By Timothy K. Egan Before placement in a computed tomography scanner, a patient is fitted with an immobilization device. Immobilization ensures that the same area of the patient is scanned
More informationCancer Endorsement Maintenance 2011-Maintenance Measures
Measure Number Title Description Measure Steward 0210 Proportion receiving chemotherapy in the last 14 days of life 0211 Proportion with more than one emergency room visit in the last days of life 0212
More informationTesticular Malignancies /8/15
Collecting Cancer Data: Testis 2014-2015 NAACCR Webinar Series January 8, 2015 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationAllinaHealthSystems 1
2018 Dimensions in Oncology Genitourinary Cancer Disclosures I have no financial or commercial relationships relevant to this presentation. Matthew O Shaughnessy, MD, PhD Director of Urologic Oncology
More informationNATIONAL QUALITY FORUM
Cancer Endorsement Maintenance Table of Submitted Measures Phase I 0210 1 Proportion receiving chemotherapy in the last 14 days of life Percentage of patients who died from cancer receiving chemotherapy
More informationQuiz 1. Assign Race 1, Race 2 and Spanish Hispanic Origin to the following scenarios.
Quiz 1 Assign Race 1, Race 2 and Spanish Hispanic Origin to the following scenarios. 1. 62 year old Brazilian female Race 1 Race 2 Spanish/Hispanic Origin 2. 43 year old Asian male born in Japan Race 1
More informationOverview. What is Cancer? Prostate Cancer 3/2/2014. Davis A Romney, MD Ironwood Cancer and Research Centers Feb 18, 2014
Prostate Cancer Davis A Romney, MD Ironwood Cancer and Research Centers Feb 18, 2014 Overview Start with the basics: Definition of cancer Most common cancers in men Prostate, lung, and colon cancers Cancer
More informationMEDICAL POLICY Genetic and Protein Biomarkers for Diagnosis and Risk Assessment of
POLICY: PG0367 ORIGINAL EFFECTIVE: 08/26/16 LAST REVIEW: 09/27/18 MEDICAL POLICY Genetic and Protein Biomarkers for Diagnosis and Risk Assessment of Prostate Cancer GUIDELINES This policy does not certify
More informationDr.R.Venkateswari Assistant Professor Department of Medical Biochemistry University of Madras, Taramani Campus, Chennai
Dr.R.Venkateswari Assistant Professor Department of Medical Biochemistry University of Madras, Taramani Campus, Chennai 600113 +919884208143 vengiteja06@yahoo.co.in 1 KNOWING CANCER Cancer is a disease
More informationAnaplastic A term used to describe cancer cells that divide rapidly and have little or no resemblance to normal cells.
Oncology Terminology A Adenocarcinoma A cancerous tumor that arises in or resembles glandular tissue. Adjunct agent In cancer therapy, a drug or substance used in addition to the primary therapy. Adjuvant
More informationProstate Biopsy. Prostate Biopsy. We canʼt go backwards: Screening has helped!
We canʼt go backwards: Screening has helped! Robert E. Donohue M.D. Denver V.A. Medical Center University of Colorado Prostate Biopsy Is cure necessary; when it is possible? Is cure possible; when it is
More information1. Benign Prostate Hyperplexia (BPH) 2. Prostate Cancer (PCa)
Objectives: Our first segment focused in the anatomy and functions of the prostate gland, to get a clear understanding of the male Genito-Urinary System. Now, we will explore two of the main problems associated
More informationFACULTY MEMBERSHIP APPLICATION Tulane Cancer Center
FACULTY MEMBERSHIP APPLICATION Tulane Cancer Center 1430 Tulane Ave., Box SL-68, New Orleans, LA 70112-2699 J. Bennett Johnston Building, Mezzanine (Floor 1A), Suite A102 (504) 988-6060, fax (504) 988-6077,
More informationRunning Title: Utility of HCG Washout in Cervical LND FNA
AACE Clinical Case Reports Rapid Electronic Articles in Press Rapid Electronic Articles in Press are preprinted manuscripts that have been reviewed and accepted for publication, but have yet to be edited,
More informationMECHANISMS OF HUMAN DISEASE: LABORATORY SESSION CYTOPATHOLOGY Monday, April 26, 2013 FACULTY COPY
GOAL: MECHANISMS OF HUMAN DISEASE: LABORATORY SESSION CYTOPATHOLOGY Monday, April 26, 2013 FACULTY COPY 1. Understated the role of cytopathology in the clinical management of the patient and recognize
More informationACOS Inquiry and Response Selected Inquires CS Tumor Size/Extension Evaluation, CS Lymph Nodes Evaluation, CS Metastasis at Diagnosis Evaluation *
ACOS Inquiry and Response Selected Inquires CS Tumor Size/Extension Evaluation, CS Lymph Nodes Evaluation, CS Metastasis at Diagnosis Evaluation * CS Tumor Size/Extension Evaluation 24842 12/11/2007: Q:
More informationCardiff MRCS OSCE Courses Testicular Cancer
Testicular Cancer Scenario: A 40-year-old male presents to the surgical out-patient clinic with a 6-8 week history of a painless lump in his left scrotum. He however complains of a dull ache in the scrotum
More informationChemotherapy for Urological Cancers
Chemotherapy for Urologic Cancers Matthew Rettig, MD Associate Professor Department of Medicine Division of Hematology-Oncology Department of Urology Medical Director, Prostate Cancer Program Institute
More informationQ&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1
Collecting Cancer Data: Prostate NAACCR 2010-2011 Webinar Series May 5, 2011 Q&A Please submit all questions concerning webinar content through the Q&A panel Overview NAACCR 2010-2011 Webinar Series 1
More informationHarmesh Naik, MD. Hope Cancer Clinic PERSONALIZED CANCER TREATMENT USING LATEST IN MOLECULAR BIOLOGY
Harmesh Naik, MD. Hope Cancer Clinic PERSONALIZED CANCER TREATMENT USING LATEST IN MOLECULAR BIOLOGY A NEW GENE A DAY.WHILE YOU ARE ENJOYING MORNING COFFEE From cancer.gov GOALS FOR THE CME TODAY A brief
More informationBreast Cancer Diagnosis, Treatment and Follow-up
Breast Cancer Diagnosis, Treatment and Follow-up What is breast cancer? Each of the body s organs, including the breast, is made up of many types of cells. Normally, healthy cells grow and divide to produce
More informationProstate cancer screening: a wobble Balance. Elias NAOUM PGY-4 Urology Hotel-Dieu de France Universite Saint Joseph
Prostate cancer screening: a wobble Balance Elias NAOUM PGY-4 Urology Hotel-Dieu de France Universite Saint Joseph Epidemiology Most common non skin malignancy in men in developed countries Third leading
More informationConsensus and Controversies in Cancer of Prostate BASIS FOR FURHTER STUDIES. Luis A. Linares MD FACRO Medical Director
BASIS FOR FURHTER STUDIES Main controversies In prostate Cancer: 1-Screening 2-Management Observation Surgery Standard Laparoscopic Robotic Radiation: (no discussion on Cryosurgery-RF etc.) Standard SBRT
More informationAnalyte Specimen Demographic Reference Range Units
Acetone Negative titer Alanine aminotransferase (ALT/SGPT) 10-49 U/L Albumin 3.2-4.8 g/dl Alcohol < 10 Alpha-fetoprotein (AFP) < 1.3-8.1 ng/ml Alkaline phosphatase 0 7 days 7 30 days 1 3 3 6 6 12 1 3 3
More informationPSA Screening and Prostate Cancer. Rishi Modh, MD
PSA Screening and Prostate Cancer Rishi Modh, MD ABOUT ME From Tampa Bay Went to Berkeley Prep University of Miami for Undergraduate - 4 years University of Miami for Medical School - 4 Years University
More informationDr. Shari Srinivasan, Consultant Chemical Pathologist, Tallaght Hospital, Dublin 24, Ireland
Draft Laboratory Testing for Tumour Markers V1.0 Authors Dr. Shari Srinivasan, Consultant Chemical Pathologist, Tallaght Hospital, Dublin 24, Ireland Dr. Gerard Boran, Consultant Chemical Pathologist,
More informationAJCC 7th Edition Handbook Errata as of 9/21/10
5 81 Larynx ICD-O-3 Topography Codes Delete C32.3 Laryngeal cartilage 5 81 Larynx ICD-O-3 Topography Codes Add an asterisk after C32.8 5 81 Larynx ICD-O-3 Topography Codes Add an asterisk after C32.9 5
More informationNavigators Lead the Way
RN Navigators Their Role in patients with Cancers of the GI tract Navigators Lead the Way Nurse Navigator Defined Nurse Navigator A clinically trained individual responsible for the identification and
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationWhat is Testicular cancer?
Testicular Cancer What is Testicular cancer? Testicular cancer is a disease in which cancer cells form in the tissues of one or both testicles. The testicles are 2 egg-shaped glands located inside the
More informationPET/CT Frequently Asked Questions
PET/CT Frequently Asked Questions General Q: Is FDG PET specific for cancer? A: No, it is a marker of metabolism. In general, any disease that causes increased metabolism can result in increased FDG uptake
More informationWhat Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen).
What Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen). It is a very common cancer in men; some cancers grow very slowly,
More informationTumor Immunology. Tumor (latin) = swelling
Tumor Immunology Tumor (latin) = swelling benign tumor malignant tumor Tumor immunology : the study of the types of antigens that are expressed by tumors how the immune system recognizes and responds to
More informationCDC & Florida DOH Attribution
FCDS Annual Educational Conference Tampa, Florida July 19, 2018 Steven Peace, CTR 1 CDC & Florida DOH Attribution We acknowledge the Centers for Disease Control and Prevention, for its support of the Florida
More informationOncology 101. Cancer Basics
Oncology 101 Cancer Basics What Will You Learn? What is Cancer and How Does It Develop? Cancer Diagnosis and Staging Cancer Treatment What is Cancer? Cancer is a group of more than 100 different diseases
More informationControversies in Prostate Cancer Screening
Controversies in Prostate Cancer Screening William J Catalona, MD Northwestern University Chicago Disclosure: Beckman Coulter, a manufacturer of PSA assays, provides research support PSA Screening Recommendations
More informationCancer of Unknown Primary (CUP) Protocol
1 Department of Oncology. Cancer of Unknown Primary (CUP) Protocol Version: Document type: Document sponsor Designation Document author [ s] Designation[s] Approving committee / Group Ratified by: Date
More informationCase Scenario 1 Discharge Summary Pathology Report Final Diagnosis: Oncology Consult
Case Scenario 1 Discharge Summary A 31-year-old Brazilian male presented with a 6 month history of right-sided scrotal swelling. Backache was present for 2 months and a history of right epididymitis was
More informationNote: The cause of testicular neoplasms remains unknown
- In the 15- to 34-year-old age group, they are the most common tumors of men. - Tumors of the testis are a heterogeneous group of neoplasms that include: I. Germ cell tumors : 95%; all are malignant.
More information4.5% 4.0% 3.5% 3.0% 2.5% 2.0% 1.5% 1.0% 0.5% 0.0% < >80 Current Age (Yrs)
Biomedical Engineering for Global Health Lecture Twelve Prostate Cancer Early Detection Prostate Cancer: Statistics Prostate gland contributes enzymes, nutrients and other secretions to semen. United States:
More informationApplications of IHC. Determination of the primary site in metastatic tumors of unknown origin
Applications of IHC Determination of the primary site in metastatic tumors of unknown origin Classification of tumors that appear 'undifferentiated' by standard light microscopy Precise classification
More informationQUALIFIED CLINICAL DATA REGISTRY (QCDR) 2017 MEASURE SPECIFICATIONS
QOPI5 Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented (Lower Score - Better) Percentage of adult patients with metastatic solid tumors
More information2011 PROSTATE BRACHYTHERAPY STUDY
20 PROSTATE BRACHYTHERAPY STUDY CRITERIA Patients receiving prostate brachytherapy at Cox from 2002-200. In this study, we will look at patients with the following prognostic features: PSA
More informationHealth Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015
Health Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015 Outline Epidemiology of prostate cancer Purpose of screening Method of screening Contemporary screening trials
More informationIndex. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic
More informationThe Tumor (T), the Lymph Nodes (N), and the Cancer Spread (M)
The Tumor (T), the Lymph Nodes (N), and the Cancer Spread (M) Primary tumor (T) TX: Main tumor cannot be measured. T0: Main tumor cannot be found. T1, T2, T3, T4: The size and/or extent of the main tumor.
More informationBiochemistry of Cancer and Tumor Markers
Biochemistry of Cancer and Tumor Markers The term cancer applies to a group of diseases in which cells grow abnormally and form a malignant tumor. It is a long term multistage genetic process. The first
More informationA superficial radiotherapy B single pass curettage C excision with 2 mm margins D excision with 5 mm margins E Mohs micrographic surgery.
1- A 63-year-old woman presents with a non-healing lesion on her right temple that has been present for over two years. On examination there is a 6 mm well defined lesion with central ulceration, telangiectasia
More informationCase Scenario 1 Discharge Summary Pathology Report Final Diagnosis: Oncology Consult
Case Scenario 1 Discharge Summary A 31-year-old Brazilian male presented with a 6 month history of right-sided scrotal swelling. Backache was present for 2 months and a history of right epididymitis was
More informationCancer Prevention & Control in Adolescent & Young Adult Survivors
+ Cancer Prevention & Control in Adolescent & Young Adult Survivors NCPF Workshop July 15-16, 2013 Patricia A. Ganz, MD UCLA Schools of Medicine & Public Health Jonsson Comprehensive Cancer Center + Overview
More informationProstate Cancer Case Study 1. Medical Student Case-Based Learning
Prostate Cancer Case Study 1 Medical Student Case-Based Learning The Case of Mr. Powers Prostatic Nodule The effervescent Mr. Powers is found by his primary care provider to have a prostatic nodule. You
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationBreast cancer staging update. Ekaterini Tsiapali, MD, FACS MedStar Regional Breast Program Site Director
Breast cancer staging update Ekaterini Tsiapali, MD, FACS MedStar Regional Breast Program Site Director 1 1 Review of the AJCC 8 th edition breast cancer staging Review of genomic assays as stage modifiers
More information10/2/2018 OBJECTIVES PROSTATE HEALTH BACKGROUND THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION
THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION Lenette Walters, MS, MT(ASCP) Medical Affairs Manager Beckman Coulter, Inc. *phi is a calculation using the values from PSA, fpsa and p2psa
More informationBREAST SURGERY PROGRESS TEST Name:
General Surgery Residency Program Excellent surgeons BREAST SURGERY PROGRESS TEST Name: Choose the BEST answer for the following questions. 1. All of the following factors are associated with an increased
More informationAFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options
AFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options INTRODUCTION This booklet describes how prostate cancer develops, how it affects the body and the current treatment methods. Although
More informationISPOR 4 th Asia Pacific Conference IP2 Gilberto de Lima Lopes
Health Economic Considerations for Personalized Medicine in Asia: Using Genomic Profiling to Guide Treatment Decisions in Early Breast Cancer Gilberto de Lima Lopes, Jr., M.D., M.B.A Assistant Director
More informationBreast Cancer. Excess Estrogen Exposure. Alcohol use + Pytoestrogens? Abortion. Infertility treatment?
Breast Cancer Breast Cancer Excess Estrogen Exposure Nulliparity or late pregnancy + Early menarche + Late menopause + Cystic ovarian disease + External estrogens exposure + Breast Cancer Excess Estrogen
More informationSomerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services. Cancer of Unknown Primary Network Site Specific Group. Clinical Guidelines
Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services Cancer of Unknown Primary Network Site Specific Group Revision due: April 2019 Page 1 of 11 VERSION CONTROL THIS IS A CONTROLLED DOCUMENT.
More informationCase Discussions: Prostate Cancer
Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of
More informationQuiz. b. 4 High grade c. 9 Unknown
Quiz 1. 10/11/12 CT scan abdomen/pelvis: Metastatic liver disease with probable primary colon malignancy. 10/17/12 Colonoscopy with polypectomy: Adenocarcinoma of sigmoid colon measuring at least 6 mm
More informationWhen to worry, when to test?
Focus on CME at the University of Calgary Prostate Cancer: When to worry, when to test? Bryan J. Donnelly, MSc, MCh, FRCSI, FRCSC Presented at a Canadian College of Family Practitioner s conference (October
More informationHematology 101. Rachid Baz, M.D. 5/16/2014
Hematology 101 Rachid Baz, M.D. 5/16/2014 Florida 101 Epidemiology Estimated prevalence 8,000 individuals in U.S (compare with 80,000 MM patients) Annual age adjusted incidence 3-8/million-year 1 More
More informationThermo Scientific B R A H M S Biomarkers Tumor Marker Assays. Excellent precision. Confident cancer monitoring
Thermo Scientific B R A H M S Biomarkers Tumor Marker Assays Excellent precision Confident cancer monitoring Thermo Scientific B R A H M S Biomarkers Tumor Markers Parameter Clinical Interest Product Technology
More informationPSA To screen or not to screen? Darrel Drachenberg, MD, FRCSC
PSA To screen or not to screen? Darrel Drachenberg, MD, FRCSC Disclosures Faculty / Speaker s name: Darrel Drachenberg Relationships with commercial interests: Grants/Research Support: None Speakers Bureau/Honoraria:
More information4/20/2015. Serum Protein Tumor Marker Assays: A Need for Constant Vigilance. Learning Objectives. Estimated Cancer Deaths in the US in 2015
Serum Protein Tumor Marker Assays: A Need for Constant Vigilance Nichole Korpi-Steiner, PhD, DABCC, FACB University of North Carolina Chapel Hill, NC Learning Objectives Describe what comprises an ideal
More informationMEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site
POLICY: PG0364 ORIGINAL EFFECTIVE: 04/22/16 LAST REVIEW: 07/26/18 MEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site GUIDELINES This policy does not certify benefits or authorization
More information